BeiGene/ CNE100005XT6 /
| 2024-05-31 9:00:00 AM | Chg. -0.90 | Volume | Bid9:00:02 AM | Ask9:00:05 AM | High | Low |
|---|---|---|---|---|---|---|
| 121.52CNY | -0.74% | 1.24 mill. Turnover: 153.04 mill. |
121.52Bid Size: 11,743 | 121.60Ask Size: 6,200 | 127.48 | 121.52 |
GlobeNewswire
05-28
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
GlobeNewswire
05-14
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-02
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-02
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business...
GlobeNewswire
04-11
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire
03-28
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
03-05
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the ...
GlobeNewswire
02-27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire
02-27
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights ...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
